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INTRODUCTION                                                               
Pulmonary arterial hypertension (PAH) in childhood is a progressive and, in 
most cases, fatal disease of the pulmonary vasculature. Although seen 
regularly by cardiologists, it is less commonly seen by paediatricians. It affects 
fewer than two adults per million population, and probably less children. The 
clinical course can be one of rapid deterioration, with death occurring within 
three years of diagnosis in adults, and less than one year in children. (1,2)
In the last decade, a better understanding of the pathophysiology has led 
to signifi cant improvements in the treatment options, which now include 
oral calcium channel blockers, anticoagulation, continuous intravenous 
prostacyclin infusion, aerosolised prostacyclin, endothelin receptor blockers 
and more recently a type 5 phosphodiesterase inhibitor, namely sildenafi l. (3) 
As is often the case when managing children, most of our knowledge is 
based on experience and fi ndings in adults.
Chronic pulmonary arterial hypertension 
in children
DEFINITION                                                                        
The defi nition of pulmonary arterial hypertension in children is the same 
as that in adults. The normal pulmonary vasculature is a low pressure system 
with less than one quarter the pressure and one tenth the resistance to 
fl ow observed in the systemic vascular bed. Pulmonary hypertension refers 
to the haemodynamic state in which the pressure measured in the 
pulmonary artery is elevated. By consensus, pulmonary arterial hypertension 
is regarded as a mean pulmonary artery pressure greater than 25 mm Hg 
at rest and greater than 30 mm Hg with exercise in the setting of normal 
or reduced cardiac output, with a normal pulmonary artery wedge 
pressure, namely 15 mm Hg or less. (4)
Children may have normal to high pulmonary artery pressure at rest, but 
have an exaggerated increase in response to exertion, therefore exercise 
haemodynamics are important for the diagnosis. (5) Unfortunately, this is 
often not possible in the younger children.
CLASSIFICATION AND CAUSES                                    
A greater understanding of the disease has led to a rethinking of the 
diagnostic classifi cation of pulmonary arterial hypertension. The fi rst 
classifi cation of pulmonary arterial hypertension was after the World 
Health Organization (WHO) Conference on pulmonary hypertension 
in 1973. The second was at the 2nd WHO Conference in 1998 in 
Evian, France and the most recent at the 3rd World Conference in Venice 
in 2003.
This classifi cation separates pulmonary arterial hypertension from 
pulmonary venous hypertension, pulmonary hypertension associated with 
respiratory system abnormalities and hypoxia as well as a range of other 
less common disorders which can also cause pulmonary arterial 
hypertension.
The term primary pulmonary hypertension was, until recently, the term 
used to describe familial disease, or sporadic disease of unknown cause. At 
the World Pulmonary Arterial Hypertension Symposium in 2003, the term 
“primary pulmonary hypertension” was set aside and replaced with 
idiopathic pulmonary arterial hypertension (IPAH). Where a hereditary 
basis is supported by genetic fi ndings, the term familial pulmonary arterial 
hypertension (FPAH) is to be used. In these patients  pulmonary arterial 
hypertension (PAH) is differentiated from pulmonary hypertension caused 
by left heart disease, chronic lung disease, hypoxaemia, chronic thrombotic 
or embolic disorders affecting the lungs and other infectious or infl ammatory 
triggers (Table 1). 
This classifi cation system is useful in that it provides evidence-based clinical 
practice guidelines and a rationale for treatment necessary for the approval 
by drug regulating authorities of new drugs for pulmonary arterial 
hypertension. (7)
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 Pulmonary arterial hypertension, although not 
common in children, has a poor prognosis. The defi nition, modern 
classifi cation, causes and pathogenesis are discussed. Although 
the pathogenesis is complex and not completely understood, we 
now have a better understanding of it. The mechanisms and 
structural alterations underlying vasoconstriction of the pulmonary 
vasculature, remodelling of the pulmonary vessel wall and 
progressive obstruction and obliteration of the vascular bed with 
thrombosis are set out with the different mediators involved. 
Diagnosis can be diffi cult and a high level of suspicion is necessary 
to achieve an early diagnosis. The approach to management includes 
a methodical workup. The medication options discussed are based 





Idiopathic pulmonary arterial hypertension
Idiopathic pulmonary arterial hypertension is pulmonary arterial 
hypertension of  an unknown cause. The histopathological changes  are 
angioproliferative plexiform lesions of endothelial cells, muscularization of 
precapillary arterioles, intimal endothelial cell proliferation, and medial 
thickening due to vascular smooth muscle cell proliferation. This condition 
is rare, more commonly found in female adults than in children, and has a 
poor prognosis.
Dyspnoea is the most common presenting symptom, coupled with fatigue. 
Later signs are cyanosis and right ventricular failure. 
Familial pulmonary arterial hypertension
Genetic or familial transmission of pulmonary arterial hypertension is 
suspected or documented in approximately 6% to 10% of patients with 
pulmonary arterial hypertension. Bone Morphogenetic Protein Receptor II 
(BMPR2) mutations have been identifi ed in 50% to 90% of patients 
diagnosed with familial pulmonary arterial hypertension.(8) Familial 
pulmonary arterial hypertension is characterized by genetic predisposition, 
in which members of successive generations develop pulmonary arterial 
hypertension, usually as adults. These patients develop more severe and 
rapidly progressive disease. There is, however, incomplete penetration as 
unaffected individuals with the BMPR2 mutations are found in these 
families. (9)
Pulmonary arterial hypertension associated with other diseases
At times, pulmonary arterial hypertension occurs within the course of 
certain other diseases frequently enough to be considered as an associated, 
although not necessarily clinically observed, feature of the disease. The 
associated disease may be appropriately regarded as one of the “hits” that 
leads to pulmonary arterial hypertension and can be regarded as associated 
with, or secondary to, pulmonary arterial hypertension. 
An important member of this group in children and young adults is 
uncorrected congenital heart disease and systemic-to-pulmonary shunts 
with high pulmonary blood fl ow. The development of pulmonary arterial 
hypertension with, at times, the reversal of fl ow across the lesion 
(Eisenmenger syndrome), is most predictable when fl ow is high at a young 
age, exposing the pulmonary vasculature to systemic pressure (as with 
ventricular septal defect, patent ductus arteriosus, atrio-ventricular septal 
defect, or cyanotic congenital heart lesions with increased pulmonary 
fl ow). 
Pulmonary arterial hypertension may, however, also occur with atrial 
septal defects, which initially have a lower pulmonary artery fl ow. 
Connective tissue disease, especially the scleroderma spectrum, is also an 
important member of this group. (10) Other conditions which also exhibit 
features of pulmonary arterial hypertension are portopulmonary 
hypertension, (11) where it has major implications for survival (50% to 72% 
over 2 years), (12) exposure to certain toxic agents such as appetite 
suppressants derived from amphetamine, (13) and of signifi cance in Southern 
Africa, human immunodefi ciency virus (HIV) infection. (14) 
Pulmonary arterial hypertension and left heart disease
In signifi cant left heart disease there is an initial passive process of back 
pressure, producing elevation in pulmonary venous and, secondarily, 
pulmonary arterial pressure. Prolonged duration of pulmonary venous 
hypertension may eventually lead to an adaptive increase in pulmonary 
arteriolar resistance. Rectifying the underlying cause, e.g. mitral valve 
stenosis, usually results in the pulmonary pressures returning to normal, 
although persistent vascular changes may persist after complete 
normalization of the cardiac lesion or dysfunction. 
Pulmonary arterial hypertension with hypoxemia and lung diseases
Hypoxia and respiratory disorders of ventilation are well recognized causes 
of  pulmonary arterial hypertension. Pulmonary arterial hypertension is 
present in up to 66% of patients with stage IV chronic obstructive lung 
disease and is generally mild (15) as it is in sleep-disordered breathing. When 
sleep-disordered breathing is coupled with hypoventilation due to severe 
obesity, or associated with obstructive pulmonary disease, it results in 
severe pulmononary hypertension. (16) These are problems which affect 
children less commonly than adults.
In children, upper airway obstruction, (17) cystic fi brosis, interstitial lung 
disease, developmental hypoplasia of the lungs due to bronchopulmonary 
dysplasia secondary to prematurity, as well as severe spinal deformities and 
1.  Pulmonary arterial hypertension (PAH)
     1.1.  Idiopathic (IPAH)
    1.2.  Familial (FPAH)
    1.3.  Associated with (APAH):
 1.3.1.  Collagen vascular disease
 1.3.2.  Congenital systemic-to-pulmonary shunts
 1.3.3.  Portal hypertension
 1.3.4.  HIV infection
 1.3.5.  Drugs and toxins
 1.3.6.  Other (thyroid disorders, glycogen storage disease, Gaucher’s 
  disease, hereditary hemorrhagic telangiectasia, 
  hemoglobinopathies, myeloproliferative disorders, splenectomy)
 1.4.  Associated with signifi cant venous or capillary involvement
 1.4.1.  Pulmonary veno-occlusive disease (PVOD)
 1.4.2.  Pulmonary capillary hemangiomatosis (PCH)
 1.5.  Persistent pulmonary hypertension of the newborn
2.  Pulmonary hypertension with left heart disease
 2.1.  Left-sided atrial or ventricular heart disease
 2.2.  Left-sided valvular heart disease
3.  Pulmonary hypertension associated with lung diseases and/or hypoxaemia
     3.1.  Chronic obstructive pulmonary disease
     3.2.  Interstitial lung disease
     3.3.  Sleep-disordered breathing
     3.4.  Alveolar hypoventilation disorders
     3.5.  Chronic exposure to high altitude
     3.6.  Developmental abnormalities
4.  Pulmonary hypertension due to chronic thrombotic and/or embolic 
 disease (CTEPH)
     4.1.  Thromboembolic obstruction of proximal pulmonary arteries
     4.2.  Thromboembolic obstruction of distal pulmonary arteries
     4.3.  Nonthrombotic pulmonary embolism (tumor, parasites, 
  foreign material)
5.  Miscellaneous
      Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of   
  pulmonary vessels (adenopathy, tumor, fi brosing mediastinitis)
Reproduced from Simonneau et al.(6)






neuromuscular disease are possible causes. Children have a more reactive 
pulmonary vasculature than adults, which is particularly susceptible to the 
effects of hypoxia, exercise and other stimuli with resulting pulmonary 
arterial hypertension. (18) 
Pulmonary arterial hypertension and chronic embolic disease
Chronic thromboembolic pulmonary hypertension is observed in up to 
3% of patients who survive an acute embolism. (19) It may occur in the 
absence of a clear history of acute pulmonary embolism. In patients with a 
history of pulmonary embolism, a relatively asymptomatic interval may 
precede presentation when more advanced arteriopathy or right ventricular 
failure has developed. 
In children with chronic thromboembolic disease pulmonary arterial 
hypertension is uncommon, but may complicate sickle cell anaemia, 
bacterial endocarditis, a ventricular to atrial shunt for hydrocephalus and 
schistosomiasis. (20)
PATHOPHYSIOLOGY                                                        
The pathogenesis of pulmonary arterial hypertension is complex and 
not completely understood. Factors thought to be important are 
vasoconstriction of the pulmonary vasculature, remodelling of the 
pulmonary vessel wall and progressive obstruction and obliteration of the 
vascular bed with thrombosis. Signifi cantly rising pulmonary vascular 
resistance eventually leads to right heart failure and later death. (21)
The mechanisms and structural alterations underlying these developments 
that lead to the progression of pulmonary vasculopathy have become 
increasingly better understood. Some or all of these changes may play a 
role in all forms of pulmonary arterial hypertension. However, some 
molecular and cellular substrates with their histopathologic consequences 
have been associated with particular types of pulmonary arterial 
hypertension. 
The development of pulmonary vascular disease frequently originates with 
the interaction of a predisposing state and one or more inciting stimuli. This 
concept is referred to as the “multiple-hit hypothesis”. (22) Two or more 
“hits” may consist of a genetic substrate combined with an additional 
genetic condition, either a mutation or polymorphism, a coexisting disease, 
or an environmental exposure.
Once a combination of possible initiating factors exists, various mechanisms 
are activated that lead to vascular constriction, cellular proliferation, and a 
prothrombotic state. This then results in pulmonary arterial hypertension 
and its clinical outcome in varying degrees, depending on the underlying 
and causative factors. 
Vasoconstriction    
Conditions resulting in hypoxaemia, especially if chronic, can lead to 
pulmonary vasoconstriction due to effects on the endothelium and smooth 
muscle cells of the arterial walls. (23) 
Vasoactive mediators that affect tone and structural remodelling of the 
pulmonary vasculature, such as nitric oxide and endothelin-1, have been 
implicated in the pathophysiology of pulmonary hypertension. (24) Reduced 
activity of the enzyme nitric oxide syntetase impairs the continuous supply 
of nitric oxide from the endothelium resulting in vasoconstriction, (25) while 
the vascular effects of nitric oxide depend on its augmentation 
of cyclic guanosine monophosphate content in smooth muscle. 
Cyclic guanosine monophosphate is degraded by cyclic guanosine 
monophosphatediesterase, which is increased in pulmonary arterial 
hypertension. 
Thromboxane A2, a vasoconstrictor and proplatelet aggregator and 
prostacyclin, a vasodilator with antiplatelet properties, are both important 
in regulating vasomotor tone. An imbalance between these vasoactive 
substances has been implicated in the pathogenesis of secondary pulmonary 
arterial hypertension. (26) 
Cellular proliferation
Endothelial injury, dysfunction from hypoxia, infl ammation or damage from 
haemodynamic shear stresses can cause an imbalance between a 
vasoconstrictive-mitogenic mediator and a vasodilator-antiproliferative 
mediator.  This can result in an increase in vasomotor tone and vasoreactivity 
with smooth muscle proliferation. Thromboxane A2 and endothelin-1 are 
vasoconstrictors and mitogens, while prostacyclin and nitric oxide are 
vasodilators with antiproliferative effects. (27)  
Prothrombosis
Endothelial injury causes the migration of smooth muscle cells into the 
vascular wall, leading to medial hypertrophy and hyperplasia and, with the 
excessive release of locally active mediators, promotes a procoagulant state 
with intravascular thrombosis causing further obstruction. (27) 
Eventually there is muscularisation of the pulmonary arterioles with 
proliferation of smooth muscle in the intima of the small pulmonary 
arteries, leading to intimal fi brosis and proliferation of smooth muscle in the 
pulmonary veins and venules. (29)
As discussed above, there are complex interactions between the different 
factors that contribute to the mechanisms involved.
CLINICAL PRESENTATION                                             
Patients with pulmonary hypertension may be asymptomatic with few 
clinical signs, especially in the early stages of the disease. They generally 
present with a spectrum of symptoms and signs due to impaired oxygen 
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transport and later reduced cardiac output.  Where pulmonary hypertension 
is secondary, the causative condition may be the only initial presenting 
clinical abnormality.
Presenting symptoms
The most frequent presenting symptom is dyspnoea, which initially is usually 
exertional. (30) As the disease progresses dyspnoea is present in virtually all 
patients. With further progression it may even be present at rest.
Further complaints commonly found are fatigue, weakness and exertion 
intolerance, depending on the age of the child. In younger children, feeding 
problems and failure to thrive are possible. 
Since these symptoms are non-specifi c, the initial evaluation is often not 
helpful unless a related condition is recognised. Where a child presents with 
unexplained dyspnoea, pulmonary arterial hypertension must be 
considered. For example, in an infant, poor feeding with excessive sweating 
with puffy eyes could point to an underlying cardiac cause, while snoring 
and mouth breathing suggest an upper airway obstruction.
As there is a known genetic component of pulmonary hypertension, a 
family history could point the way, while possible HIV exposure warrants 
further investigation.
Physical fi ndings
The clinical signs of pulmonary arterial hypertension are often subtle and 
easily overlooked, especially in young children who normally still have some 
right ventricle dominance during the fi rst year of life.
Specifi c fi ndings that are strongly suggestive are a palpable parasternal lift 
due to a hypertrophied right ventricle and an accentuated pulmonary 
component of the second heart sound produced by an increased pressure 
at closure of the valve. Other possible fi ndings are a systolic ejection click at 
the left heart base and a systolic ejection murmur due to turbulent 
transpulmonary fl ow. With more advanced disease, a diastolic decrescendo 
murmur at the left base due to pulmonary incompetence, a pansystolic 
murmur of tricuspid regurgitation audible at the lower left sternal border 
and signs of right heart failure are possible.(30)
Cyanosis is an important sign indicative of severity. It could be due to right 
to left shunting at cardiac level, impaired intrapulmonary transfer or reduced 
cardiac output. Associated digital clubbing is seldom found in idiopathic 
pulmonary arterial hypertension and raises the possibility of congenital 
heart disease or chronic lung disease. (31)   
The physical examination may provide some insight into the possible 
aetiology where a primary underlying cause is considered.
DIAGNOSTIC EVALUATION                                           
Chest radiography
Chest roentgenography, although not very sensitive, may provide the fi rst 
clue to the presence of pulmonary arterial hypertension. Once the disease 
has progressed, enlargement of the central pulmonary arteries with 
peripheral pruning of the pulmonary vasculature on the posteroanterior 
view and reduction in retrosternal air space on the lateral view due to right 
ventricular hypertrophy may be visible. Most patients with asymptomatic 
pulmonary hypertension have normal chest radiography fi ndings. No 
correlation seems to exist between the extent of the radiological fi ndings 
and the degree of pulmonary hypertension. (32)   
The chest radiogram can also be useful in defi ning coexistent conditions 
related to or causing pulmonary arterial hypertension, such as pulmonary 
venous congestion or lung infi ltrations in HIV disease.
Electrocardiogram
Pulmonary arterial hypertension causes right ventricular hypertrophy and 
later right heart dilation. The electrocardiogram (ECG) will demonstrate 
right-axis deviation, right ventricular hypertrophy, and anterior ST- and T-
wave abnormalities consistent with a right ventricular strain pattern, 
although it is relatively insensitive and non-specifi c. (30) In severe cases with 
right atrial enlargement a tall P wave is seen in leads II III and aVF.
Echocardiogram
Transthoracic doppler echocardiography is an essential tool for 
demonstrating the presence of pulmonary arterial hypertension. When 
present, doppler velocity measurement of a tricuspid regurgitant signal for 
estimation of right ventricular systolic pressure is important. There is a high 
level of correlation of estimated right ventricular systolic pressure with 
invasively measured pulmonary artery pressure. (33) Individual results may 
overestimate or underestimate actual pulmonary artery systolic pressures. 
When indicated, further confi rmation with invasive studies is required. 
Echocardiography provides additional data important in the evaluation of 
pulmonary arterial hypertension, including assessment of right ventricular 
size and function.
The severity of pulmonary hypertension can also be determined using 
right ventricular outfl ow patterns and time intervals including pre-ejection 
period, acceleration and deceleration, relaxation and contraction times. (34) 
These may be especially usefull when tricuspid and pulmonary regurgitation 
are not present.  
Echocardiography provides left heart function analysis and morphology 
and can provide information indicating elevated pulmonary venous 






it provides the best assessment of congenital heart disease and, in most 
cases, an assessment of the pulmonary artery pressure in this situation.
Evaluating other risk factors for pulmonary arterial hypertension
In patients with unexplained pulmonary hypertension, serological testing 
for connective tissue disease and HIV infection should be performed. 
Where indicated, scarcer conditions such as sickle cell anaemia, bacterial 
endocarditis and schistosomiasis should be excluded.
In patients old enough, pulmonary function testing is a necessary part of 
the initial evaluation in order to exclude, or when present, determine the 
contribution of any underlying airway or parenchymal disease. Oximetry 
and arterial blood oxygenation is part of the evaluation for the presence 
and severity of lung disease. (32) 
Where an upper airway obstruction is considered, otolaryngeal evaluation 
should be performed. (17)
Genetic evaluation and counselling
Although BMPR2 mutations are clearly associated with heritable pulmonary 
arterial hypertension, testing poses potential diffi culties. Only 10% to 20% 
of carriers of the gene mutation actually exhibit pulmonary hypertension. 
Testing for BMPR2 mutations is currently available at a very limited number 
of institutions. (35) Where there is a family history, genetic counselling is 
indicated.
Right heart catheterisation with vasodilator testing
Right heart catheterisation remains the gold standard by which the diagnosis 
of pulmonary arterial hypertension is made. It not only provides an 
indication of disease severity, but is diagnostic in excluding other aetiologies 
such as congenital heart disease, extracardiac shunts and left heart 
disease. 
The degree to which mean pulmonary arterial pressure and pulmonary 
vascular resistance can be decreased acutely by the administration of fast-
acting, short-duration vasodilators refl ects the extent to which vascular 
smooth muscle constriction is contributing to the hypertensive state. 
Because the vasodilator response has considerable therapeutic implications 
in idiopathic pulmonary arterial hypertension, most patients should 
undergo a vasodilator trial at the time of initial cardiac catheterisation. 
Intravenous epoprostenol, intravenous adenosine, or inhaled nitric oxide 
are commonly used for acute vasodilator testing. (36) 
Lung biopsy
Lung biopsy is not routinely done because of the risk. Histopathological 
fi ndings are often non-specifi c. (37) In those circumstances where tissue 
examination might offer specifi c information, it can be considered to 
establish a diagnosis of conditions such as bronchiolitis or granulomatous 
pulmonary disease. 
TREATMENT                                                                       
1. General measures
Any underlying or associated disease that can be treated specifi cally takes 
priority over non-specifi c treatment. In children this is clearly of importance, 
as they have a longer anticipated lifespan than adults. Examples are the 
timely treatment of congenital heart lesions with a high pulmonary fl ow or 
the removal of lymphoid tissue causing upper airway obstruction.
Exercise and especially heavy physical activity or isotonic exercises should 
be avoided. Low-level aerobic exercise, such as walking, should be 
encouraged in older children. 
Exposure to high altitudes must be avoided, because this may produce 
hypoxic pulmonary vasoconstriction. Patients who have to fl y may require 
oxygen on commercial aircraft. 
Because respiratory infections are particularly troublesome in these 
children, a full immunization program is advised, including immunisation 
against infl uenza and pneumococcal pneumonia. All respiratory infections 
need immediate and aggressive treatment.
Concomitant medications that include vasoconstricting sinus or cold 
preparations should be avoided. Certain pulmonary arterial hypertension 
medications have specifi c medication interactions, such as cyclosporine 
with bosentan and organic nitrates with sildenafi l, and are consequently 
contraindicated for simultaneous use. Patients receiving warfarin 
anticoagulation should be counselled about the many agents that interact 
with this medication.
Diuretics are indicated to manage volume overload due to right ventricular 
failure. In some cases digoxin and intravenous diuretics are required. In 
these cases, serum electrolytes and renal function should be monitored.  
Hypoxaemia is a potent pulmonary vasoconstrictor. Most experts 
recommend oxygen supplementation to maintain arterial oxygen saturation 
above 90%. 
2. Medication
Based on our improved knowledge of the pathogenesis of pulmonary 
arterial hypertension, therapy is aimed at inhibition of cell proliferation, 
increase of vasodilation or inhibition of vasoconstriction, inhibition of 
infl ammatory, prothrombotic and proliferative mediators and increase of 
their antagonists.
The treatment of pulmonary arterial hypertension with drugs is complex 
and at times involves the use of sophisticated delivery systems, often 
intravenous, which have not been formally studied in children. Guidelines 
have been published for the management of pulmonary arterial 
hypertension in adults, and the treatment of children tends to follow a 
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similar strategy although few studies have been done on children. (38)  When 
dealing with children, careful consideration must be given to the patients 
and their carers, since the benefi t of intravenous treatment will depend on 
their ability to accept and manage drug administration, often through a 
central line which is not always practical, especially in younger children. Oral 
and other “non-parenteral” therapies are usually preferable in children. 
2.1  Calcium channel blockers
  Acute vasodilator testing in the cardiac catheter laboratory should 
be performed to determine appropriate treatment. The defi nition  of 
a positive response is a reduction of mean pulmonary arterial 
pressure by at least 10 mm Hg to a value of 40 mm Hg or less.  A 
higher proportion of children are acute “responders” compared to  
adults. (39) Patients with this response are most likely to have a 
benefi cial hemodynamic and clinical response to treatment with 
calcium channel blockers. (40) Those failing to achieve this response are 
unlikely to improve with calcium channel blocker therapy and their 
condition could worsen. (41) Children who were initially “acute 
responders”, may become “non-responders” over time. (42) Improved 
survival has been observed in both adults and children who 
responded to an acute vasodilator challenge and were treated with 
nifedipine in addition to conventional anti-failure treatment with 
digoxin, diuretics, and supplemental oxygen. (43) 
  Dihydropyridine calcium channel blockers, such as nifedipine and 
amlodipine that act on vascular smooth muscle are preferred. 
Nifedipine has a shorter  half life and is preferred over amlodipine. 
Negative inotropic calcium channel blockers, such as verapamil, 
should be avoided. (44) The  optimum dose of calcium channel blockers 
in children with pulmonary hypertension is unknown. They should be 
introduced carefully and the dose titrated as tolerated.
 
2.2  Anticoagulation
  Anticoagulation with warfarin  has a survival benefi t in adults (45) and 
consequently warfarin is commonly given to children.  The international 
normalised ratio (INR) depends on the risk of benefi t and bleeding. 
In general, the INR range is 1.5–2. In children with chronic 
thromboembolic disease, the recommendation is to aim for a higher 
INR; while in active toddlers and children with thrombocytopenia the 
recommendation is an INR < 1.5. (46) In small children, the need for 
ongoing INR blood tests and the risk of signifi cant bleeding can be 
problematic for everyone involved and warfarin is often not 
prescribed.
2.3  Prostacyclins
  Prostacyclin, a metabolite of arachidonic acid is produced in  vascular 
endothelium. It is a potent pulmonary and systemic  vasodilator and 
has an inhibitory effect on platelet aggregation. (47) 
2.3.1 Epoprostenol
  When given as a continuous intravenous infusion, epoprostenol, a 
prostacyclin, improves exercise tolerance, symptoms,  haemodynamics, 
and survival in children and adults. (48) Epoprostenol decreases 
pulmonary vascular resistance and improves the survival in both 
responders and non-responders to acute testing. (49) This raises the 
question of a mechanism of action other than only vasodilation. 
Antiproliferative and vascular remodelling effects are proposed.(50) 
Side effects include jaw pain, rash, diarrhoea, nausea and vomiting, 
light headedness, headache and fl ushing. The usual starting dose in 
children is the same as in adults, namely 2 ng/kg/min with titration 
until the maximum tolerated dose is reached. (51)
  Administration of epoprostenol requires a central venous line and 
a continuous infusion pump to be worn by the child. Interruption 
of the infusion or pump failure can result in a life-threatening 
hypertensive crises. Other complications are catheter-related sepsis 
and thrombosis. 
2.3.2 Iloprost nebulised
  Iloprost is a stable analogue of prostacyclin with a longer half life of 
15–30 minutes compared to 2–3 minutes for epoprostenol. The 
duration of action for iloprost is about 60 minutes, thus frequent 
nebulisations are necessary. (52) Drug delivery direct to the lungs 
avoids a central intravenous catheter but needs regular inhalations, 
which requires compliance, often diffi cult in children. Side effects are 
similar, but more common. (52)
2.4  Endothelin receptor antagonists
  Endothelin-1, a potent vasoconstrictor and muscle mitogen, is 
increased in lung tissue and plasma of patients with pulmonary 
arterial hypertension. (47)
2.4.1 Bosentan
  Bosentan is a competitive endothelin-A and endothelin-B receptor 
antagonist. It is the only oral agent with a licence for the treatment of 
adult pulmonary arterial hypertension.  Bonestan has been studied in 
19 children aged between 3–15 years with idiopathic pulmonary 
arterial hypertension or pulmonary arterial hypertension related to 
congenital heart disease. Changes in exercise capacity and  WHO 
class at 12 weeks was not signifi cantly different from baseline 
conditions. The most frequent adverse effects were fl ushing, headache, 
and elevated liver enzymes. (53) Bosentan is being used in infants and 
children with severe disease. The oral dosage form is an enormous 
advantage in this age group. Clinical improvement has been seen in 
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